CMPS
Compass Pathways Plc
Stock NASDAQ – Stock Market Prices, News & Analysis
Compass Pathways Plc is a biotechnology company focused on developing psilocybin-based therapies for the treatment of depression.
Compass Pathways Plc
CMPS
Compass Pathways Plc is a biotechnology company focused on developing psilocybin-based therapies for the treatment of depression.
Price history of Compass Pathways Plc
Price history of Compass Pathways Plc
Performance & Momentum
Strategic Analysis
Compass Pathways Plc • 2026
Compass Pathways is positioned as an advanced-stage biotech focused on psilocybin-assisted therapies, with a clear emphasis on treatment-resistant depression and psychiatric disorders with high unmet medical need. Its equity appeal rests more on the potential value of its pipeline and clinical data than on an already mature commercial model.
- Pioneering position in a therapeutic approach that is still underexplored in psychiatry
- Exposure to a large addressable market driven by the need for innovative solutions against depression
- High speculative visibility linked to clinical and regulatory milestones
- Heavy dependence on clinical trial outcomes and health authority decisions
- Lack of meaningful recurring revenue until commercialization is established
Momentum appears favorable but remains typical of a biotech stock that is highly sensitive to market expectations. The recent trend reflects renewed investor interest in the story, while still leaving intact a history of strong volatility and uneven long-term performance. For investors, this points to a speculative conviction name whose path will depend primarily on upcoming clinical and regulatory developments.
Similar stocks to Compass Pathways Plc
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
